Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:GNLXNASDAQ:KMDANASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.65+5.1%$1.41$1.11▼$5.00$439.13M1.771.50 million shs1.45 million shsGNLXGenelux$2.45-3.5%$2.67$1.60▼$5.89$92.45M-0.33193,116 shs127,667 shsKMDAKamada$6.89-0.9%$6.58$4.74▼$9.16$396.04M0.9490,830 shs52,890 shsVERVVerve Therapeutics$4.24-1.2%$4.56$2.86▼$9.31$377.97M1.821.87 million shs2.75 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+1.95%+2.61%+18.05%-13.74%-59.95%GNLXGenelux-1.55%-7.64%-11.81%-44.30%-3.05%KMDAKamada+4.83%+1.16%+3.89%-2.11%+31.13%VERVVerve Therapeutics-1.61%-6.94%-25.52%-32.01%-18.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics3.4084 of 5 stars3.54.00.00.03.33.30.6GNLXGenelux1.6557 of 5 stars3.62.00.00.03.30.00.0KMDAKamada3.85 of 5 stars3.43.00.00.03.41.73.1VERVVerve Therapeutics3.2611 of 5 stars4.51.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32464.85% UpsideGNLXGenelux 3.20Buy$17.75624.49% UpsideKMDAKamada 2.75Moderate Buy$14.67112.87% UpsideVERVVerve Therapeutics 3.00Buy$25.75507.31% UpsideCurrent Analyst Ratings BreakdownLatest GNLX, AUTL, KMDA, and VERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $39.004/14/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $25.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M48.73N/AN/A$0.64 per share2.58GNLXGenelux$8K11,556.34N/AN/A$0.73 per share3.36KMDAKamada$167.24M2.37$0.38 per share17.90$4.25 per share1.62VERVVerve Therapeutics$59.61M6.34N/AN/A$7.31 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%8/14/2025 (Estimated)GNLXGenelux-$28.30M-$0.88N/AN/AN/AN/A-105.05%-80.16%8/13/2025 (Estimated)KMDAKamada$8.28M$0.2924.6121.530.979.92%6.30%4.49%8/13/2025 (Estimated)VERVVerve Therapeutics-$200.07M-$2.11N/AN/AN/A-807.65%-35.23%-27.65%8/14/2025 (Estimated)Latest GNLX, AUTL, KMDA, and VERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/A3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ALatest GNLX, AUTL, KMDA, and VERV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2025KMDAKamada--$0.203/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69GNLXGeneluxN/A6.476.47KMDAKamadaN/A4.842.73VERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%GNLXGenelux37.33%KMDAKamada20.38%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%GNLXGenelux9.30%KMDAKamada36.10%VERVVerve Therapeutics19.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableGNLXGenelux1037.74 million31.33 millionNot OptionableKMDAKamada36057.48 million36.73 millionOptionableVERVVerve Therapeutics11089.14 million68.32 millionOptionableGNLX, AUTL, KMDA, and VERV HeadlinesRecent News About These CompaniesVerve Therapeutics to Participate in Upcoming Investor ConferencesMay 28 at 7:00 AM | globenewswire.comExperimental drug promising to bring down bad cholesterol by up to 69% completes early stage trialMay 26 at 11:36 AM | theprint.inVerve Therapeutics, Inc. (NASDAQ:VERV) Position Lessened by Rafferty Asset Management LLCMay 25 at 4:04 AM | marketbeat.comNorthern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)May 25 at 3:07 AM | marketbeat.comWall Street Zen Upgrades Verve Therapeutics (NASDAQ:VERV) to "Hold"May 24, 2025 | marketbeat.comGroundbreaking treatment for bad cholesterol on the horizon? This single-use drug shows some promiseMay 24, 2025 | cnbctv18.comStrokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.May 23, 2025 | msn.comHC Wainwright Has Optimistic Outlook of VERV FY2025 EarningsMay 23, 2025 | marketbeat.comMillennium Management LLC Sells 1,105,050 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)May 23, 2025 | marketbeat.comFY2025 EPS Estimate for Verve Therapeutics Lifted by AnalystMay 23, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for VERV FY2026 Earnings?May 22, 2025 | marketbeat.comResearch Analysts Offer Predictions for VERV FY2026 EarningsMay 22, 2025 | americanbankingnews.com3 Top Genomics Stocks to Add to Your Portfolio in 2025May 21, 2025 | zacks.comVerve Therapeutics, Inc. (NASDAQ:VERV) Position Raised by Vestal Point Capital LPMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys New Position in Verve Therapeutics, Inc. (NASDAQ:VERV)May 21, 2025 | marketbeat.comVerve Therapeutics Leads The Charge With 2 Other Promising Penny StocksMay 20, 2025 | finance.yahoo.comTema Etfs LLC Invests $503,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)May 20, 2025 | marketbeat.comCantor Fitzgerald Analysts Raise Earnings Estimates for VERVMay 20, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Outlook for VERV EarningsMay 20, 2025 | marketbeat.comQ3 EPS Forecast for Verve Therapeutics Lifted by AnalystMay 20, 2025 | marketbeat.comQ3 EPS Forecast for Verve Therapeutics Raised by AnalystMay 20, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNLX, AUTL, KMDA, and VERV Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.65 +0.08 (+5.10%) Closing price 04:00 PM EasternExtended Trading$1.64 -0.01 (-0.61%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Genelux NASDAQ:GNLX$2.45 -0.09 (-3.54%) Closing price 04:00 PM EasternExtended Trading$2.51 +0.06 (+2.45%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Kamada NASDAQ:KMDA$6.89 -0.06 (-0.86%) Closing price 04:00 PM EasternExtended Trading$6.87 -0.02 (-0.29%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Verve Therapeutics NASDAQ:VERV$4.24 -0.05 (-1.17%) Closing price 04:00 PM EasternExtended Trading$4.19 -0.05 (-1.18%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
